Exploring management strategies to optimise corporate value

Alicia Ramírez-Orellana, Silvia Giralt-Escobar and Cristina Blanco-González-Tejero

European Journal of Innovation Management, 2024, vol. 28, issue 8, 4177-4201

Abstract: PurposeThis paper explores effective management strategies to optimise corporate value in the pharmaceutical industry. It uses key variables such as research and development (R&D), board gender diversity, and environmental, social and governance (ESG) factors.Design/methodology/approachGiven the dynamic and multifaceted nature of corporate innovation and its impact on performance, 53 pharmaceutical companies were examined using partial least squares structural equation modelling (PLS-SEM). This methodology enabled exploration of causal and predictive relationships in corporate value and management.FindingsGreater investment in R&D drives innovation and future growth. Despite the short-term financial impact, R&D investment reflects a strategic emphasis on long-term growth and sustainability in the pharmaceutical industry. Management effectiveness mediates the effects of gender diversity on increasing corporate value. The ESG score is the least relevant variable for assessing the value of pharmaceutical companies. It contributes to improving management practices but is not fully considered in the overall corporate value of a company taking into account the selected database.Practical implicationsPharmaceutical companies can use these findings to adjust and optimise their investment in R&D. They can thus direct their strategies towards more ethical and sustainable practices, thereby enhancing effectiveness and competitiveness. The combination of these elements provides an opportunity to develop integrated management strategies.Originality/valueThis research explores innovative strategies to enhance corporate value, emphasising the pivotal role of R&D and ESG factors. It reveals the intricacies of the pharmaceutical landscape and provides solutions for organisational strategy.

Keywords: Innovation; Corporate value; ESG; R&D; Board gender diversity; Pharmaceutical industry (search for similar items in EconPapers)
Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.emerald.com/ejim/article/28/8/4177/125 ... rategies-to-optimise (text/html)
https://www.emerald.com/ejim/article-pdf/28/8/4177 ... m-04-2024-0396en.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eme:ejimpp:ejim-04-2024-0396

DOI: 10.1108/EJIM-04-2024-0396

Access Statistics for this article

European Journal of Innovation Management is currently edited by Dr Vincenzo Corvello

More articles in European Journal of Innovation Management from Emerald Group Publishing Limited
Bibliographic data for series maintained by Emerald Support ().